In the case of tarlatamab, the molecule binds to CD3 receptors on T cells and DLL3 on SCLC cells with the aim of stimulating the immune system to destroy the tumour. It’s a well-established ...

T he U.K.'s Medicines and Healthcare products Regulatory Agency has approved Amgen's (NASDAQ:AMGN) tarlatamab, also known as Imdyllytra, for the treatment of small cell lung cancer that has spread ...